Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Haemonetics (HAE) Debt to Equity (2016 - 2025)

Haemonetics has reported Debt to Equity over the past 16 years, most recently at $1.34 for Q4 2025.

  • Quarterly results put Debt to Equity at $1.34 for Q4 2025, down 0.51% from a year ago — trailing twelve months through Dec 2025 was $1.34 (down 0.51% YoY), and the annual figure for FY2025 was $1.49, up 77.32%.
  • Debt to Equity for Q4 2025 was $1.34 at Haemonetics, down from $1.44 in the prior quarter.
  • Over the last five years, Debt to Equity for HAE hit a ceiling of $1.49 in Q1 2025 and a floor of $0.84 in Q1 2024.
  • Median Debt to Equity over the past 5 years was $1.09 (2021), compared with a mean of $1.13.
  • Biggest five-year swings in Debt to Equity: surged 146.89% in 2022 and later decreased 23.96% in 2023.
  • Haemonetics' Debt to Equity stood at $1.12 in 2021, then decreased by 11.59% to $0.99 in 2022, then dropped by 6.6% to $0.92 in 2023, then soared by 46.35% to $1.35 in 2024, then decreased by 0.51% to $1.34 in 2025.
  • The last three reported values for Debt to Equity were $1.34 (Q4 2025), $1.44 (Q3 2025), and $1.39 (Q2 2025) per Business Quant data.